Leonard P. Wesley, Ph.D,President - Leonard Wesley was a computer scientist and senior researcher at SRI International for over twelve years. At SRI he co-developed some of the underlying algorithms that will be used in MedLex's line of disease management applications. He is also the current president of Intellex, a company that he founded in 1991 that develops commercially viable decision support and real-time embedded system software for NASA, DARPA, Air Force, and Boeing. Dr. Wesley has over 18 years experience with succesfully developing and deploying applications for commercial and government clients. He has over 40 referred publications in the areas of automated decision support and software embedded systems.

Richard Lee, M.D. - Co-founder Richard Lee is a full-time family physician and Assistant Clinical Professor at the Stanford Family Practice Clinic. His consulting will focus on helping to identify decision support factors related to patient compliance when drug candidates can be manufactured and marketed in different forms.





Michael Gauthier, M.S. - CEO and Founder, e-tractions, Bedford MA., Before founding e-tractions, Mike was president and CEO of MGA Software, a software and services company providing sophisticated simulation technology to the pharmaceutical, automotive, aerospace, and chemical industries. Prior to that, Mike served as VP of Technology and Operations for ARTIS, LTD, a satellite network provider servicing a number of industries including natural gas buyers and sellers. Before ARTIS, Mike was a principal at Mercer Management Consulting, one of the largest management consulting copanies in the world. At Mercer, Mike lead the strategic technology practice where he helped financial institutions and health care companies manage the rapid change in technology and business climate. Mike holds a Masters in Management from the Sloan School at MIT and a B.S. in Mathematics and Physics from Connecticut College.

Deepak Thakkar, Ph.D. - SGI. Dr. Thakkar joined SGI in late 2006 and is responsible for the marketing of SGI solutions in the BioSciences market segment. He has a Ph.D. in pharmaceutical chemistry from West Virginia University, where he conducted research on developing oligonucleotide based therapies to knock-out breast cancer genes. Dr. Thakkar also and has an undergraduate degree in pharmacy, from Bombay University, India.

Before joining SGI, Dr. Thakkar held several senior management positions in marketing and business development at genomics and life science informatics companies such as Rosetta Inpharmatics (now part of Merck), Silicon Genetics (now part of Agilent Technologies), Genedata and InforSense. Deepak has been instrumental in developing the pharmaceutical and biotech markets at these companies and in their global expansion, with particular emphasis on Asian markets. He managed the Asia business unit at Genedata and established the Japan business unit while at Rosetta Inpharmatics. Deepak is an active member of the American Association of Pharmaceutical Scientists and also sits on the business advisory boards of genomics and business intelligence companies in the Silicon Valley.

Allan J. Prager, M.B.A. - Allan Prager is an experienced entrepreneur and strategic consultant to the pharmaceutical and biotech industries.  He was co-founder, President & CEO of Juvenon, Inc. (Orinda, CA), a company formed to commercialize products based on a biotech patent held by the University of California, Berkeley.  He oversaw investor recruitment, product development, clinical testing, establishment of commercial operations, international licensing, and achievement of profitability.  He built sales to $4.6 million.  Previously, he was co-founder of PHT Corporation (Boston, MA), a software company that has developed web-based products for the conduct and management of clinical trials. At PHT he directed strategy development, early-stage funding, achievement of the company's first big-pharma customers, and recruitment of a full-time CEO. The company has been funded by several leading venture capital firms and does business with most of the world's top 20 pharmaceutical companies. Earlier, he participated in two leveraged buyouts and several startup companies. As a strategic consultant, he worked with senior executives as such firms as Biogen, Chiron, Genentech, Immunex, Johnson & Johnson, and Syntex. He earned a Bachelor's Degree at Stanford and an MBA at Harvard.

Kim Graham, M.A. - Vice President, Drug Development, Genencor Int’l. Inc., has overall responsibility for all projects in the development phases, from IND-enabling through phase 3, and functional responsibility for the Clinical, CMC and Project Director areas. Prior to joining Genencor in 2001, he was VP and director of Drug Evaluation in the Neurobiology Business Unit of Roche Bioscience, with responsibility for early development teams, and functional responsibility for Clinical, Regulatory, and Project Management areas. Mr. Graham held numerous positions of increasing responsibility at Syntex over a 19 year period prior to the company’s acquisition by Roche. His final position at Syntex was as VP and Director of the New Molecules Program Management Team, which was a multi-country unit with global responsibility for all aspects of development of two novel molecules. Over his career at Syntex Mr. Graham contributed to the development of numerous pharmaceutical products that have been successfully marketed. Before joining Syntex he worked for several years in the scientific information industry, developing and producing searchable information tools, both in printed and computerized forms.


Seth Michaelson, M.A., M.S. Ph.D. - Principle Scientist and Biostatistician at Theranos in Menlo Park, CA., and former Vice President, In Silico R&D at Entelos Inc., Foster City, CA. As VP at Entelos, he directed and managed all scientific R&D directed toward the development of in silico models of human disease, the biosimulation platforms which simulate their dynamics, and research projects aimed at their interrogation. He worked in conjunction with researchers in Big Pharma, these research efforts include exploiting these mathematical structures for insights into the underlying pathophysiology of the disease, applying the gained knowledge to the drug discovery and development process to build a portfolio of knowledge products. Prior to joining Entelos, Seth was VP of Information Sciences at VistaGen Inc. where he directed and managed the development of novel mathematical/statistical algorithms for the analysis and characterization of proteomic data aimed at predictive toxicology. Prior to VostaGen Seth directed the scientific support services at Roche Biosciences in Palo Alto CA.




Richard Eglen Ph.D. - VP and GM, discovery and research reagents for Perkin Elmer's Life & Analytical Sciences unit, Wellesley, Massachusetts. As VP and GM, Dr. Eglen has direct P&L and line management responsibilities for over several hundred people to further the company's cellular approach to drug discovery assays and multiplexing technologies. Before joining Perkin Elmer, he was Chief Scientific Officer, responsible for all R&D activities at DiscoveRx. He joined Syntex Research in 1987, holding several senior management positions, leading to his appointment as Vice President and Director of the Institute of Pharmacology in 1993. Following the acquisition of Syntex by Roche in 1994, Dr. Eglen participated in the design and implementation of Roche Bioscience, where he held the position of Vice President and Director of the Center for Biological Research. In 1997, he was also appointed as global coordinator of High Throughput Screening for Roche. In 2000, Dr. Eglen joined LJL Biosystems as Senior Vice President of Assays and Reagents where he was responsible for the development and implementation of the reagent assay business strategy focused on High Throughput screening. Dr. Eglen is the author of over 200 peer-reviewed papers, several book chapters and is also the inventor on several patents. He is a member of numerous professional organizations and member of several journal editorial boards. Dr. Eglen holds a Ph.D. in Pharmacology.

Roger Whiting,Ph. D. - President and Chief Scientific Officer, co-founded Roxro Pharma. Dr. Whiting has worked in the pharmaceutical industry for 30 years, initially at Beecham Research Laboratories, then at Syntex Research Scotland in the UK. In 1985 he transferred to Syntex in Palo Alto, where he led both basic research and early development and defined the company’s fledgling program in pain. With the acquisition of Syntex by F. Hoffmann- La Roche, Dr. Whiting was instrumental in creating Roche Bioscience - a novel approach to R & D in the pharmaceutical industry. Here he established and led the Neurobiology Business Unit - managing comprehensive programs in pain and urology through to clinical proof of concept. Dr. Whiting earned his B.Sc. from the University of Bradford and his graduate degree under the tutorship of Dr. M.D. Day from Aston University, both in the UK. He has authored over 100 articles, and is an inventor on 15 patents. Dr. Whiting serves on the scientific advisory boards of several biotechnology companies.





Robert E. Neger, M.D - Dr. Neger is a practicing part-time ophthalmologist with over 13 years experience conducting succesful clinical trials on efficacy and toxicity of antiviral agents. Neger had the initial idea of applying, to the biopharma industry, the decision analytic technologies that Len Wesley and his company, Intellex, has developed. Neger's major roles will be as a liaison between biopharma industry experts and Medlex staff that will be building MedLex's decision support models and products.